Loading stock…

ImmunityBio, Inc. (IBRX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

ImmunityBio, Inc.

IBRXMarket cap $10BPrice $9.7

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops immunotherapies that train the body's own immune system to hunt down cancer cells and infectious diseases. Its FDA-approved bladder cancer drug marked the first new treatment for that disease in over 20 years.

In Bastion Portfolios?

52W Return+304%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+679%10

Revenue Forecast

Rev CAGR (1y)+94%10

Rev CAGR (3y)+112%10

Rev CAGR (5y)+86%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-152%1

Net Income Margin-599%1

Free Cash Flow Margin-174%1

Debt

Net Debt/EBITDAna–

Efficiency

ROEna–

ROA-193%1

Earnings Stabilityna–

GEAR+WEAK16

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)242

P/BVna–

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-2.8%2

Dividend Yieldna–

Momentum

Short term

1 month return+20%10

3 month return+11%9

YTD return+389%10

Mid term

Price vs 52wHigh78%5

1 year return+288%10

Long term

3 year return+582%10

5 year return-0%4

Risk Shield

Price Risk

Beta1.81

Volatility100%1

Free Cash Flow

Free Cash Flow Margin-174%1

Free Cash Flow Yield-2.8%2

Quality

ROCE-56%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

IBRXImmunityBio

Revenue FY25$113M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+679%10

Revenue, next 1Y+94%10

Revenue, next 3Y, CAGR+112%10

Revenue, next 5Y, CAGR+86%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 679%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 112%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 86%/yr over five years.10/10

WATCH

Revenue grew 679%/yr over the last 3 years; forecasts see it cooling to 112%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+20%10

3-month return+11%9

YTD return+389%10

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return+288%10

3-year return+582%10

5-year return-0%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +582% over three years and -0.1% over five, ahead of 60% of the market.

It's up 288% over the past year, but 22% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+20%), over three months (+11%) and so far this year (+389%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on ImmunityBio, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

IBRXImmunityBio

Revenue FY25$113M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+679%10

Revenue, next 1Y+94%10

Revenue, next 3Y, CAGR+112%10

Revenue, next 5Y, CAGR+86%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 679%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 112%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 86%/yr over five years.10/10

WATCH

Revenue grew 679%/yr over the last 3 years; forecasts see it cooling to 112%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+20%10

3-month return+11%9

YTD return+389%10

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return+288%10

3-year return+582%10

5-year return-0%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +582% over three years and -0.1% over five, ahead of 60% of the market.

It's up 288% over the past year, but 22% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+20%), over three months (+11%) and so far this year (+389%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on ImmunityBio, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community